CSPC Pharmaceutical (HKG:1093) said it began a phase 3 trial of SYS 6010 in China, according to a Hong Kong bourse filing Tuesday.
The firm will study a combination of the drug with enlonstobart to study its effectiveness in patients with completely resected stage II-III B non-small cell lung cancer who have no actionable genomic alterations and have not achieved major pathological response.